• Baicalein Workflows for Cancer and Inflammation

  2026-09-19

  Baicalein supports mechanism-focused studies of 12-LOX activity, cancer-cell responses, apoptosis, and inflammatory signaling. This practical guide combines solvent handling, orthogonal assays, and lessons from a chemotherapy-neurotoxicity study without overextending evidence from a different flavonoid.

• Cy3 NHS Ester (Non-Sulfonated): Practical Guide

  2026-09-18

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent label for accessible amino groups on proteins, peptides, and oligonucleotides. It is appropriate when the workflow tolerates DMSO or DMF, but its water insolubility makes it a poor choice for aqueous-only protocols or particularly solvent-sensitive biomolecules.

• Partial BACE Inhibition Preserves Synaptic Function

  2026-09-18

  Satir et al. used optical electrophysiology in primary cortical rat neurons to test whether moderate β-secretase inhibition can lower amyloid β secretion without disrupting synaptic transmission. Their results identify a practical exposure boundary: partial BACE inhibition reduced amyloid production while stronger inhibition impaired neuronal signaling.

• VX-661: Designing Better CFTR Rescue Assays

  2026-09-17

  VX-661 is a F508del CFTR corrector whose rescue signal depends on trafficking, proteostasis, and channel gating. This article presents an assay-design framework that separates these mechanisms and applies variant-aware insights from recent CFTR research.

• AZD1480: Practical JAK2 Inhibitor Workflows

  2026-09-17

  AZD1480 is an ATP-competitive JAK2 inhibitor for dissecting tumor-intrinsic STAT3 signaling, adaptive cytokine responses, and drug combinations. This workflow-focused guide covers phosphoprotein assays, myeloma and solid-tumor models, immune-conditioned systems, formulation, and troubleshooting.

• SB525334: TGF-beta1 Receptor Inhibitor Workflows

  2026-09-16

  SB525334 provides a selective way to test whether ALK5-dependent TGF-beta signaling drives profibrotic, renal, or wound-repair phenotypes. This practical guide connects Smad2/3 pathway assays with fibrosis models and the angiogenic and osteo-immune findings of a recent diabetic foot ulcer study.

• Tau Ser356, NUAK Inhibition, and Alzheimer’s Pathology

  2026-09-16

  Taylor and colleagues examined tau phosphorylation at serine 356 across Alzheimer’s disease brain tissue and ex vivo mouse and human brain-slice models. The study links p-tau Ser356 to disease-stage pathology and shows that NUAK inhibition with WZ4003 lowers this species in human brain slices, while producing broader and culture-phase-dependent effects in mouse preparations.

• EZ Cap™ Reagent AG for Functional mRNA Assays

  2026-09-15

  Explore how EZ Cap™ Reagent AG can support rigorously controlled FLCN mRNA rescue assays. This article connects mRNA cap quality with translational readouts, variant interpretation, and the experimental limits of Birt-Hogg-Dubé disease models.

• BACE Inhibition and Synaptic Transmission in AD

  2026-09-15

  Satir et al. examined whether partial β-secretase (BACE) inhibition can reduce amyloid β secretion without disrupting neuronal communication. Using optical electrophysiology alongside biochemical measurements in primary cortical neurons, the study identified a functional boundary: reductions below approximately 50% were not associated with impaired synaptic transmission, whereas stronger inhibition was.

• VX-661: F508del CFTR Corrector Guide

  2026-09-14

  This scenario-based guide explains how VX-661 (F508del CFTR corrector), SKU A2664, can be integrated into CFTR trafficking, viability, and chloride-channel experiments. It connects formulation, protocol design, proteostasis biology, and data interpretation to help researchers improve assay comparability without confusing cell health with CFTR function.

• SGI-1027: From DNMT Inhibition to Cell Death

  2026-09-14

  SGI-1027 is a DNA methyltransferase inhibitor that connects cofactor-site DNMT blockade with tumor suppressor gene reactivation and lysosome-associated cell death. This article translates recent renal cancer findings into a practical framework for designing orthogonal epigenetic and cytotoxicity assays.

• Indazole/Indole Glucagon Receptor Antagonists

  2026-09-13

  The reference study describes a modular indazole- and indole-based series of glucagon receptor antagonists derived from the MK-0893 program. Structure–activity relationship analysis identified compounds with strong in vitro activity, favorable rat pharmacokinetics, and oral efficacy in humanized glucagon receptor mouse models.

• Protein A/G Magnetic Beads: Practical IP Guide

  2026-09-12

  Protein A/G Magnetic Beads (SKU K1305) capture IgG antibodies and antibody-bound complexes from serum, culture supernatant, ascites, and other biological samples for purification, IP, Co-IP, and Ch-IP. They should be used for research workflows involving Fc-region IgG binding, not for diagnostic, clinical, or non-IgG immunoglobulin applications.

• L-Ornithine: From Urea Cycle to Liver–Brain Insight

  2026-09-11

  L-Ornithine is more than a urea cycle intermediate: it is a practical probe for connecting OTC activity, ammonia detoxification, astrocyte metabolism, and liver–brain signaling. This thought-leadership guide translates recent CNS toxicity findings into rigorous assay design and translational strategy.

• Ceruletide for Reliable Pancreatic Cell Assays

  2026-09-11

  Learn how Ceruletide (SKU B8465) can standardize CCK-receptor stimulation in pancreatic injury, viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers peptide handling, assay controls, interpretation, and practical product-selection criteria.

8574 records 1/572 page Next 12345 下5页 Last page